I-Mab Strengthens Global Leadership with Appointment of Neil K. Warma as General Manager of U.S. Subsidiary

SHANGHAI and GAITHERSBURG, Md., Sept. 12, 2019 /PRNewswire/ --Tianjing BiotechnologyTianjing Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as “Tianjing Biologics”), an innovative biopharmaceutical company based in China with a global focus on the field of tumor immunology and autoimmune disease treatment, announced on September 3, 2019, the appointment ofNeil K. Warmaas General Manager of the U.S. subsidiary. Mr. Warma will be based in the United States and will lead the team to enhance I-Mab’s R&D and business operational capabilities in the U.S.

Mr. Warma has over 25 years of experience in the global healthcare industry. Prior to joining Tianjing Biotechnology, Mr. Warma served as President and Chief Executive Officer of Opexa Therapeutics (NASDAQ: OPXA), where he led the company.Development of a personalized cell therapy platform, continuously optimized through clinical development.He also held key positions at Novartis headquarters, including Head of Global Pharmaceutical Policy and Market Access. Previously, Mr. Warma served as Chief Executive Officer of Viron Medical and as Co-founder and President of MedExact.

“We are delighted that Neil has joined I-Mab as General Manager of our U.S. subsidiary at this critical juncture in the company’s rapid growth, working with us to enhance our global presence,” stated Dr. Zang Jingwu, Founder and Chairman of I-Mab. “Neil brings extensive experience in the international pharmaceutical industry and a strong track record in the pharmaceutical and biotechnology sectors. We believe his appointment will significantly strengthen our international capabilities and leadership, propelling I-Mab’s rapid evolution into a globally influential, integrated biopharmaceutical company.”

“It is a great honor to join Tianjing Biotechnology, a company dedicated to developing ‘first-in-class’”Best-in-class"a company with potential for innovative biologics, boasting a strong reputation and successful R&D experience in the field of innovation." Warma stated, "It is very exciting that several projects in Tianjing Biotechnology's rich pipeline of innovative drugs have already entered late-stage clinical trials. The company's expansion in the U.S. and globally is an inevitable trend for its development, and I am full of anticipation for this."

Mr. Warma earned an Honours degree in Neuroscience from the University of Toronto and holds an MBA from the Schulich School of Business at York University in Canada.